Lanean...
Randomized Controlled Trial of Atomoxetine for Cognitive Dysfunction in Early Huntington Disease
BACKGROUND: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of atte...
Gorde:
| Egile Nagusiak: | , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2009
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3806326/ https://ncbi.nlm.nih.gov/pubmed/19745649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0b013e3181b2ac0a |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|